Passive Broad-Spectrum Influenza Immunoprophylaxis

Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include th...

Full description

Saved in:
Bibliographic Details
Published in:Influenza Research and Treatment 2014-01, Vol.2014 (2014), p.2-10
Main Authors: Berry, Cassandra M., Penhale, William J., Sangster, Mark Y.
Format: Article
Language:English
Subjects:
Avian flu
Causes of
Development and progression
Drug resistance
Fatalities
Immunization
Immunoglobulins
Immunology
Infections
Influenza
Influenza vaccines
Investigations
Mortality
Pandemics
Physiological aspects
Prevention
Review
Swine flu
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3
cites cdi_FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3
container_end_page 10
container_issue 2014
container_start_page 2
container_title Influenza Research and Treatment
container_volume 2014
creator Berry, Cassandra M.
Penhale, William J.
Sangster, Mark Y.
description Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies.
doi_str_mv 10.1155/2014/267594
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4190013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A417737987</galeid><airiti_id>P20151216006_201412_201512160005_201512160005_2_10</airiti_id><sourcerecordid>A417737987</sourcerecordid><originalsourceid>FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3</originalsourceid><addsrcrecordid>eNqFkl1rHCEUhofS0oQ0V70vC4VSUibxY9TxJpCGfiwEGmh7La5zzBhmdKozaZNfX7eT7mZDoSp41Oe84vEtipcYHWPM2AlBuDohXDBZPSn2CZKoxFTKp5u4RnvFYUrXKDeOaiyq58UeYZTUXIr9glzqlNwNLN7HoJvy6wBmjFO_WHrbTeDv9GLZ95MPQwxDe9vpXy69KJ5Z3SU4vJ8Piu8fP3w7_1xefPm0PD-7KHXFaFVKLZmAleXGsjzYSkoOtCYCKDcMga0RF8YSyDGCTFtoqF1pzYQxmlh6UJzOusO06qEx4MeoOzVE1-t4q4J2avfEu1ZdhRtVYYkQplng7b1ADD8mSKPqXTLQddpDmJLCHFdcSsFxRl8_Qq_DFH1-nsICSco4Y3xLXekOlPM25HvNWlSdVVgIKmQtMnX8Dyr3Bnpnggfr8v5OwpsHCS3obmxT6KbRBZ92wXczaGJIKYLdFAMjtbaDWttBzXbI9KuH9duwfz8_A0cz0Drf6J_uP2rLGdYuutFt63OZKYYJ5tlffzIwUdstxB4tsjj9Dc9BzgA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709356556</pqid></control><display><type>article</type><title>Passive Broad-Spectrum Influenza Immunoprophylaxis</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Berry, Cassandra M. ; Penhale, William J. ; Sangster, Mark Y.</creator><contributor>Nicholls, John M.</contributor><creatorcontrib>Berry, Cassandra M. ; Penhale, William J. ; Sangster, Mark Y. ; Nicholls, John M.</creatorcontrib><description>Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies.</description><identifier>ISSN: 2090-1380</identifier><identifier>EISSN: 2090-1399</identifier><identifier>DOI: 10.1155/2014/267594</identifier><identifier>PMID: 25328697</identifier><language>eng</language><publisher>United States: Hindawi Limiteds</publisher><subject>Avian flu ; Causes of ; Development and progression ; Drug resistance ; Fatalities ; Immunization ; Immunoglobulins ; Immunology ; Infections ; Influenza ; Influenza vaccines ; Investigations ; Mortality ; Pandemics ; Physiological aspects ; Prevention ; Review ; Swine flu ; Vaccines ; Viruses</subject><ispartof>Influenza Research and Treatment, 2014-01, Vol.2014 (2014), p.2-10</ispartof><rights>Copyright © 2014 Cassandra M. Berry et al.</rights><rights>COPYRIGHT 2014 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2014 Cassandra M. Berry et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 Cassandra M. Berry et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3</citedby><cites>FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1709356556/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1709356556?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,38493,43871,44566,53766,53768,74155,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25328697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Nicholls, John M.</contributor><creatorcontrib>Berry, Cassandra M.</creatorcontrib><creatorcontrib>Penhale, William J.</creatorcontrib><creatorcontrib>Sangster, Mark Y.</creatorcontrib><title>Passive Broad-Spectrum Influenza Immunoprophylaxis</title><title>Influenza Research and Treatment</title><addtitle>Influenza Res Treat</addtitle><description>Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies.</description><subject>Avian flu</subject><subject>Causes of</subject><subject>Development and progression</subject><subject>Drug resistance</subject><subject>Fatalities</subject><subject>Immunization</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Infections</subject><subject>Influenza</subject><subject>Influenza vaccines</subject><subject>Investigations</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Physiological aspects</subject><subject>Prevention</subject><subject>Review</subject><subject>Swine flu</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>2090-1380</issn><issn>2090-1399</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNqFkl1rHCEUhofS0oQ0V70vC4VSUibxY9TxJpCGfiwEGmh7La5zzBhmdKozaZNfX7eT7mZDoSp41Oe84vEtipcYHWPM2AlBuDohXDBZPSn2CZKoxFTKp5u4RnvFYUrXKDeOaiyq58UeYZTUXIr9glzqlNwNLN7HoJvy6wBmjFO_WHrbTeDv9GLZ95MPQwxDe9vpXy69KJ5Z3SU4vJ8Piu8fP3w7_1xefPm0PD-7KHXFaFVKLZmAleXGsjzYSkoOtCYCKDcMga0RF8YSyDGCTFtoqF1pzYQxmlh6UJzOusO06qEx4MeoOzVE1-t4q4J2avfEu1ZdhRtVYYkQplng7b1ADD8mSKPqXTLQddpDmJLCHFdcSsFxRl8_Qq_DFH1-nsICSco4Y3xLXekOlPM25HvNWlSdVVgIKmQtMnX8Dyr3Bnpnggfr8v5OwpsHCS3obmxT6KbRBZ92wXczaGJIKYLdFAMjtbaDWttBzXbI9KuH9duwfz8_A0cz0Drf6J_uP2rLGdYuutFt63OZKYYJ5tlffzIwUdstxB4tsjj9Dc9BzgA</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Berry, Cassandra M.</creator><creator>Penhale, William J.</creator><creator>Sangster, Mark Y.</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Passive Broad-Spectrum Influenza Immunoprophylaxis</title><author>Berry, Cassandra M. ; Penhale, William J. ; Sangster, Mark Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Avian flu</topic><topic>Causes of</topic><topic>Development and progression</topic><topic>Drug resistance</topic><topic>Fatalities</topic><topic>Immunization</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Infections</topic><topic>Influenza</topic><topic>Influenza vaccines</topic><topic>Investigations</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Physiological aspects</topic><topic>Prevention</topic><topic>Review</topic><topic>Swine flu</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berry, Cassandra M.</creatorcontrib><creatorcontrib>Penhale, William J.</creatorcontrib><creatorcontrib>Sangster, Mark Y.</creatorcontrib><collection>Chinese Electronic Periodical Services (CEPS)</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Influenza Research and Treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berry, Cassandra M.</au><au>Penhale, William J.</au><au>Sangster, Mark Y.</au><au>Nicholls, John M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Passive Broad-Spectrum Influenza Immunoprophylaxis</atitle><jtitle>Influenza Research and Treatment</jtitle><addtitle>Influenza Res Treat</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>2</spage><epage>10</epage><pages>2-10</pages><issn>2090-1380</issn><eissn>2090-1399</eissn><abstract>Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies.</abstract><cop>United States</cop><pub>Hindawi Limiteds</pub><pmid>25328697</pmid><doi>10.1155/2014/267594</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-1380
ispartof Influenza Research and Treatment, 2014-01, Vol.2014 (2014), p.2-10
issn 2090-1380
2090-1399
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4190013
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central; Coronavirus Research Database
subjects Avian flu
Causes of
Development and progression
Drug resistance
Fatalities
Immunization
Immunoglobulins
Immunology
Infections
Influenza
Influenza vaccines
Investigations
Mortality
Pandemics
Physiological aspects
Prevention
Review
Swine flu
Vaccines
Viruses
title Passive Broad-Spectrum Influenza Immunoprophylaxis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A47%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Passive%20Broad-Spectrum%20Influenza%20Immunoprophylaxis&rft.jtitle=Influenza%20Research%20and%20Treatment&rft.au=Berry,%20Cassandra%20M.&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=2&rft.epage=10&rft.pages=2-10&rft.issn=2090-1380&rft.eissn=2090-1399&rft_id=info:doi/10.1155/2014/267594&rft_dat=%3Cgale_pubme%3EA417737987%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a4534-9a957ebf6cf5cf55b996e3827e36c50ef8067cf2e50e0e9a9fed3fbaa57cca2f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1709356556&rft_id=info:pmid/25328697&rft_galeid=A417737987&rft_airiti_id=P20151216006_201412_201512160005_201512160005_2_10&rfr_iscdi=true